Clarity Pharmaceuticals Reports Strong Response Rates in mCRPC Trial
Event summary
- Clarity Pharmaceuticals reported substantial PSA declines in 74% of evaluable participants at the 8 GBq dose level of 67Cu-SAR-bisPSMA.
- 31% of evaluable participants achieved complete response or undetectable disease across all cohorts.
- The SECuRE trial continues to recruit new and treat existing participants in the Cohort Expansion phase.
The big picture
Clarity Pharmaceuticals' SECuRE trial update highlights promising results for its radiopharmaceutical therapy in metastatic castration-resistant prostate cancer (mCRPC). The substantial PSA declines and complete responses observed suggest potential for a new therapeutic option in a heavily pre-treated patient population. The company's proprietary SAR-bisPSMA technology, which combines PSMA-targeting agents with copper isotopes, positions it as a key player in the evolving landscape of targeted radiopharmaceuticals.
What we're watching
- Clinical Efficacy
- Whether the observed response rates and complete responses will be sustained as more participants are treated.
- Regulatory Pathway
- The pace at which Clarity Pharmaceuticals advances toward Phase III registrational trials based on the current data.
- Combination Therapies
- How the combination of 67Cu-SAR-bisPSMA with enzalutamide will impact treatment outcomes in mCRPC patients.
Related topics